keyword
MENU ▼
Read by QxMD icon Read
search

ARB safety

keyword
https://www.readbyqxmd.com/read/28692311/prospective-direct-comparison-of-antihypertensive-effect-and-safety-between-high-dose-amlodipine-or-indapamide-in-hypertensive-patients-uncontrolled-by-standard-doses-of-angiotensin-receptor-blockers-and-amlodipine
#1
Keisuke Okamura, Kazuyuki Shirai, Nao Totake, Tetsu Okuda, Hidenori Urata
OBJECTIVE: When hypertension is uncontrolled by routine treatment with an angiotensin II receptor blocker (ARB) and the calcium channel blocker amlodipine (5 mg), the dose of amlodipine can be increased or a diuretic can be added. We investigated the more effective option in a prospective multicenter open-label study. METHODS: Hypertensive patients were recruited if the target blood pressure (BP) in The Japanese Society of Hypertension 2009 guideline could not be achieved with standard-dose ARB therapy and amlodipine (5 mg)...
July 10, 2017: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/28666408/effects-of-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-on-cardiovascular-events-and-residual-renal-function-in-dialysis-patients-a-meta-analysis-of-randomised-controlled-trials
#2
Youxia Liu, Xinxin Ma, Jie Zheng, Junya Jia, Tiekun Yan
BACKGROUND: The role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reducing risk of cardiovascular events (CVEs) and preserving kidney function in patients with chronic kidney disease is well-documented. However, the efficacy and safety of these agents in dialysis patients is still a controversial issue. METHODS: We systematically searched MEDLINE, Embase, Cochrane Library and Wanfang for randomized trials. The relative risk (RR) reductions were calculated with a random-effects model...
June 30, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28662936/angiotensin-receptor-neprilysin-inhibition%C3%A2-in-heart-failure-with-preserved%C3%A2-ejection-fraction-rationale-and-design-of-the-paragon-hf-trial
#3
REVIEW
Scott D Solomon, Adel R Rizkala, Jianjian Gong, Wenyan Wang, Inder S Anand, Junbo Ge, Carolyn S P Lam, Aldo P Maggioni, Felipe Martinez, Milton Packer, Marc A Pfeffer, Burkert Pieske, Margaret M Redfield, Jean L Rouleau, Dirk J Van Veldhuisen, Faiez Zannad, Michael R Zile, Akshay S Desai, Victor C Shi, Martin P Lefkowitz, John J V McMurray
OBJECTIVES: The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy and safety of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan compared with valsartan in patients with chronic heart failure and preserved ejection fraction (HFpEF). BACKGROUND: HFpEF is highly prevalent, associated with substantial morbidity and mortality, and in need of effective therapies that improve outcomes...
July 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/28648436/angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-heart-failure-and-chronic-kidney-disease-demystifying-controversies
#4
REVIEW
Kader Muneer, Anishkumar Nair
In clinical setting, congestive heart failure (CHF) and chronic kidney disease (CKD) often co-exist in patients due to common underlying predisposing factors. An intricate equilibrium between the cardiovascular and renal system is maintained through rennin angiotensin-aldosterone axis and autonomic nervous system. Consequent to favorable hemodynamic modification, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blocking (ARB) therapy have proven to be an indispensable aspect of heart failure management with morbidity and mortality benefit...
May 2017: Indian Heart Journal
https://www.readbyqxmd.com/read/28641684/novel-indications-for-commonly-used-medications-as-radiation-protectants-in-spaceflight
#5
Mark F McLaughlin, Dorit B Donoviel, Jeffrey A Jones
In the space environment, the traditional radioprotective principles of time, distance, and shielding become difficult to implement. Additionally, the complex radiation environment inherent in space, the chronic exposure timeframe, and the presence of numerous confounding variables complicate the process of creating appropriate risk models for astronaut exposure. Pharmaceutical options hold tremendous promise to attenuate acute and late effects of radiation exposure in the astronaut population. Pharmaceuticals currently approved for other indications may also offer radiation protection, modulation, or mitigation properties along with a well-established safety profile...
July 1, 2017: Aerospace Medicine and Human Performance
https://www.readbyqxmd.com/read/28618426/renoprotective-effect-of-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers-in-diabetic-patients-with-proteinuria
#6
Feng-Yi Hsu, Fang-Ju Lin, Huang-Tz Ou, Shih-Hui Huang, Chi-Chuan Wang
BACKGROUND/AIMS: Limited evidence exists on the choice of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in diabetic patients with nephropathy. We aim to assess the renal effectiveness and safety of these drugs among diabetic nephropathy patients. METHODS: This retrospective cohort study was conducted with diabetic nephropathy patients who initiated ACEI or ARB monotherapy. The primary outcome was a composite of end stage of renal disease and renal transplantation, and the secondary outcome was all-cause mortality...
2017: Kidney & Blood Pressure Research
https://www.readbyqxmd.com/read/28614052/safety-of-the-neprilysin-renin-angiotensin-system-inhibitor-lcz696
#7
REVIEW
Bo Li, Yunhe Zhao, Bo Yin, Mengfei Helian, Xinmei Wang, Feng Chen, Hongxia Zhang, Hui Sun, Bin Meng, Fengshuang An
OBJECTIVES: The combined neprilysin/rennin-angiotensin system inhibitor sacubitril/valsartan (LCZ696) has shown its superiority over ACEI/ARB therapy. In view of the existing concern of its adverse effects, we aimed to provide evidence of the safety of the new drug. RESULTS: A total of 6 randomized trials with 11,821 subjects were included in this analysis. No significant differences were found in any adverse effects between LCZ696 and ACEI/ARB or placebo groups...
May 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/28584494/efficacy-and-tolerability-of-antihypertensive-drugs-in-diabetic-and-nondiabetic-patients
#8
Maria Aslam, Mobasher Ahmad, Fizza Mobasher
OBJECTIVES OF THE STUDY: The aim of the study was to compare the efficacy and tolerability of different classes of antihypertensive drugs in diabetic and nondiabetic patients (NDPs) with essential hypertension. MATERIAL AND METHODS: The study was conducted in Mayo Hospital, Punjab Institute of Cardiology, and National Defence Hospital, Lahore, Pakistan, on 200 hypertensive patients with diabetes and 230 hypertensive patients without (Three hospitals) diabetes. Both male and female patients of age between 30 and 80 years with systolic blood pressure (SBP) above 130 mmHg and diastolic blood pressure (DBP) above 80 mmHg were enrolled in the study...
January 2017: Journal of Pharmacy & Bioallied Sciences
https://www.readbyqxmd.com/read/28497594/the-impact-of-regulatory-action-on-the-co-prescribing-of-renin-angiotensin-system-blockers-in-uk-primary-care
#9
Craig Allen, Katherine Donegan
PURPOSE: The aim of this study was to assess the impact of regulatory action taken in June 2014 on the co-prescribing of renin-angiotensin system (RAS) blockers in UK primary care. METHODS: RAS blocker prescriptions, issued between 01/01/2009-30/06/2015, were extracted from the Clinical Practice Research Datalink to estimate the quarterly prevalence (number of patients with at least one co-prescription) and incidence (number of patients first receiving a RAS blocker co-prescription) of co-prescribing...
May 11, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28496022/comparison-of-efficacy-and-safety-of-azilsartan-and-olmesartan-in-patients-with-essential-hypertension
#10
Yuhei Shiga, Shin-Ichiro Miura, Kota Motozato, Kenji Norimatsu, Masaya Yano, Yuka Hitaka, Sen Adachi, Takashi Kuwano, Ken Inoue, Asao Inoue, Kazuaki Fujisawa, Tetsuro Shirotani, Takaaki Kusumoto, Munehito Ideishi, Keijiro Saku
Many patients still have high blood pressure (BP) after treatment with angiotensin II type 1 (AT1) receptor blockers (ARBs). We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective randomized clinical trial. Sixty-four hypertensive patients who were treated with ARBs other than azilsartan and olmesartan were enrolled in this study. We randomly assigned patients to changeover from their prior ARBs to either azilsartan or olmesartan, and followed the patients for 3 months. Systolic BP (SBP) in the azilsartan group was significantly decreased at 3 months, and diastolic BP (DBP) and pulse rate (PR) in the olmesartan group showed significant reductions after 3 months...
May 12, 2017: International Heart Journal
https://www.readbyqxmd.com/read/28467382/study-of-hydroquinone-mediated-cytotoxicity-and-hypopigmentation-effects-from-uvb-irradiated-arbutin-and-deoxyarbutin
#11
Nai-Fang Chang, Yi-Shyan Chen, Ying-Ju Lin, Ting-Hsuan Tai, An-Ni Chen, Chen-Hsuan Huang, Chih-Chien Lin
Arbutin (Arb) and deoxyArbutin (dA) are both effective hypopigmentation agents. However, they are glucoside derivatives of hydroquinone (HQ), which may be decayed into HQ under higher energy environments. Therefore, safety and toxicity are very important issues when considering the usage of these compounds. However, no study has verified the properties of Ultra-Violet B (UVB)-irradiated Arb and dA. In this work, we investigated the cytotoxicity and hypopigmentation effects of UVB-irradiated Arb and dA in Detroit 551 human fibroblast cells and B16-F10 mouse melanoma cells...
May 3, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28460827/heart-failure
#12
REVIEW
Marco Metra, John R Teerlink
Heart failure is common in adults, accounting for substantial morbidity and mortality worldwide. Its prevalence is increasing because of ageing of the population and improved treatment of acute cardiovascular events, despite the efficacy of many therapies for patients with heart failure with reduced ejection fraction, such as angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists, and advanced device therapies. Combined angiotensin receptor blocker neprilysin inhibitors (ARNIs) have been associated with improvements in hospital admissions and mortality from heart failure compared with enalapril, and guidelines now recommend substitution of ACE inhibitors or ARBs with ARNIs in appropriate patients...
April 28, 2017: Lancet
https://www.readbyqxmd.com/read/28454798/the-design-of-the-valsartan-for-attenuating-disease-evolution-in-early-sarcomeric-hypertrophic-cardiomyopathy-vanish-trial
#13
RANDOMIZED CONTROLLED TRIAL
Carolyn Y Ho, John J V McMurray, Allison L Cirino, Steven D Colan, Sharlene M Day, Akshay S Desai, Steven E Lipshultz, Calum A MacRae, Ling Shi, Scott D Solomon, E John Orav, Eugene Braunwald
Hypertrophic cardiomyopathy (HCM) is often caused by sarcomere gene mutations, resulting in left ventricular hypertrophy (LVH), myocardial fibrosis, and increased risk of sudden cardiac death and heart failure. Studies in mouse models of sarcomeric HCM demonstrated that early treatment with an angiotensin receptor blocker (ARB) reduced development of LVH and fibrosis. In contrast, prior human studies using ARBs for HCM have targeted heterogeneous adult cohorts with well-established disease. The VANISH trial is testing the safety and feasibility of disease-modifying therapy with an ARB in genotyped HCM patients with early disease...
May 2017: American Heart Journal
https://www.readbyqxmd.com/read/28415944/pentoxifylline-plus-aceis-arbs-for-proteinuria-and-kidney-function-in-chronic-kidney-disease-a-meta-analysis
#14
Dong Liu, Li-Na Wang, Hong-Xia Li, Ping Huang, Liang-Bo Qu, Fei-Yan Chen
Objective This meta-analysis aimed to investigate the efficacy and safety of pentoxifylline (PTF) plus angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) for proteinuria and kidney function in chronic kidney disease (CKD). Methods CENTRAL, EMBASE, Ovid-MEDLINE, PubMed, and CNKI were searched for relevant, randomized, controlled trials (RCTs). A meta-analysis was performed to review the effect of PTF plus ACEIs/ARBs vs. ACEIs/ARBs alone on proteinuria and kidney function in CKD...
April 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28395659/abelmoschus-manihot-a-traditional-chinese-medicine-versus-losartan-potassium-for-treating-iga-nephropathy-study-protocol-for-a-randomized-controlled-trial
#15
Ping Li, Yi-Zhi Chen, Hong-Li Lin, Zhao-Hui Ni, Yong-Li Zhan, Rong Wang, Hong-Tao Yang, Jing-Ai Fang, Nian-Song Wang, Wen-Ge Li, Xue-Feng Sun, Xiang-Mei Chen
BACKGROUND: IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide, but effective therapy remains limited and many patients progress to end-stage renal disease (ESRD). Only angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin-receptor blockers (ARB) show a high level of evidence (1B level) of being of value in the treatment for IgAN according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. However, traditional Chinese medicine has raised attention in kidney disease research...
April 11, 2017: Trials
https://www.readbyqxmd.com/read/28369341/fecal-microbiota-transplantation-in-patients-with-blood-disorders-inhibits-gut-colonization-with-antibiotic-resistant-bacteria-results-of-a-prospective-single-center-study
#16
Jaroslaw Bilinski, Pawel Grzesiowski, Nikolaj Sorensen, Krzysztof Madry, Jacek Muszynski, Katarzyna Robak, Marta Wroblewska, Tomasz Dzieciatkowski, Grazyna Dulny, Jadwiga Dwilewicz-Trojaczek, Wieslaw Wiktor-Jedrzejczak, Grzegorz W Basak
BACKGROUND: Patients with blood disorders colonized with antibiotic-resistant bacteria (ARB) are prone to systemic infections that are difficult to treat. Reintroduction of commensal bacteria in a murine model of enterococcal colonization of the gut can lead to eradication of enterococci. We hypothesized that fecal microbiota transplantation (FMT) could be used to eradicate ARB in humans. METHODS: Participants colonized with ARB were treated with intraduodenal FMT according to a prospective protocol (NCT02461199)...
March 24, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28353612/the-effectiveness-and-safety-of-angiotensin-converting-enzyme-inhibition-or-receptor-blockade-in-vascular-diseases-in-patients-with-hemodialysis
#17
Kuang-Ming Liao, Hui-Teng Cheng, Yi-Hsuan Lee, Chung-Yu Chen
Patients with end-stage renal disease (ESRD) who are on hemodialysis have high risk of vascular diseases. Our study sought to examine whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin type 1 receptor blockers (ARBs) could reduce the frequencies of cardiovascular and cerebrovascular events in patients receiving hemodialysis using the medication possession ratio (MPR) method of analysis.This retrospective cohort study identified cases of ESRD with dialysis from the National Health Insurance Research Database between 1999 and 2006, and used Cox-regression methods to evaluate risk of poor outcomes...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28290831/-efficacy-and-safety-of-a-fixed-combination-of-perindopril-arginine-and-amlodipine-in-patients-with-hypertension-uncontrolled-by-treatment-with-angiotensin-ii-receptor-blockers-in-real-clinical-practice-results-of-the-prevoshodstvo-superiority-program
#18
O D Ostroumova
The article presents preliminary results of a subanalysis of PREVOSHODSTVO (SUPERIORITY) phase IV study. Aim of this subanalysis was to assess efficacy and tolerability of a fixed-dose perindopril/amlodipine combination (FDPAC) in patients with arterial hypertension (AP) uncontrolled on previous treatment with angiotensin receptor blockers (ARBs). MATERIAL AND METHODS: We included in this analysis 125 patients (70.4% women, mean age 57.2+/-10.0 years), final analysis of efficacy was performed on 124 patients...
January 2017: Kardiologiia
https://www.readbyqxmd.com/read/28290827/-azilsartan-medoxomil-capabilities-in-arterial-hypertension-and-obesity
#19
Y A Vasyuk, E Y Shupenina, V V Nesvetov, E A Nesterova, E I Golubkova
Arterial hypertension (AH) is one of the most common cardiovascular disease. Angiotensin II (AT II), the hormone of renin-angiotensin-aldosterone system, realizes its negative effects through AT 1 receptors - application point of angiotensin receptor blockers (ARB). Due to different dissociation AT 1 receptors properties some ARBs are more effective than others. Multiply multicenter randomized and observational studies approve the effectiveness and safety of azilsartan medoxomil in patients with AH 1-2 grade...
December 2016: Kardiologiia
https://www.readbyqxmd.com/read/28155610/mineralocorticoid-antagonists-in-esrd-an-overview-of-their-efficacy-and-safety
#20
Panagiotis I Georgianos, Vasilios Vaios, Theodoros Eleftheriadis, Pantelis Zebekakis, Vassilios Liakopoulos
Add-on mineralocorticoid-receptor-antagonists (MRAs) spironolactone and eplerenone can enhance the cardioprotective action of angiotensin-converting-enzyme-inhibitors (ACEIs), angiotensin-receptor-blockers (ARBs) and/or β-blockers in non-dialysis patients with congestive heart failure (CHF) and reduced left ventricular (LV) ejection fraction. The efficacy and safety of MRAs among patients on chronic dialysis is less well studied. A growing body of evidence derived from small randomized studies suggests that MRA therapy may improve a number of surrogate cardiovascular (CV) risk factors (i...
February 1, 2017: Current Vascular Pharmacology
keyword
keyword
82037
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"